AI, Google and DeepMind
AI-developed drug will be in trials by year-end, says Google’s Hassabis
Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big pharmaceutical partners, which are keen to lower expenses and boost efficiency of the costly drug development process.
This new approach, based on natural selection, dramatically improves the reliability of large language models for practical ...
A new study shows that large language models make trade-offs to avoid pain, with possible implications for future AI welfare.
A demo car ad created with Veo 2 from Google DeepMind is so realistic that it's hard to spot the amazing locations, ...
The director of the corporation’s scientific laboratory points to genomics, nuclear fusion and the development of new ...
Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups ...
A string of startups are racing to build models that can produce better and better software. They claim it’s the shortest ...
With "Mind Evolution" LLMs can use search and genetic algorithms to generate and combine different solutions and find the optimal one.
Google DeepMind AI for Science Scholarships are now available, offering African students the opportunity to pursue ...
AI creatives with access to Google’s Veo 2 text-to-video tool say it’s another “leap forward” for video generation Veo 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback